Risk Stratification of Chronic Heart Failure Patients by Multiple Biomarkers Implications of BNP, H-FABP, and PTX3

• Ishino Mitsunori

  Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine

• Takeishi Yasuchika

  First Department of Internal Medicine, Fukushima Medical University

• Niizeki Takeshi

  Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine

• Watanabe Tetsu

  Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine

• Nitobe Joji

  Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine

• Miyamoto Takuya

  Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine

• Miyashita Takehiko

  Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine

• Kitahara Tatsuro

  Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine

• Suzuki Satoshi

  Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine

• Sasaki Toshiki

  Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine

• Bilim Olga

  Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine

• Kubota Isao

  Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine

書誌事項

タイトル別名

• Implications of BNP, H-FABP, and PTX3

抄録

Background B-type natriuretic peptide (BNP), heart-type fatty acid-binding protein (H-FABP), and pentraxin 3 (PTX3) each predict adverse cardiac events in chronic heart failure (CHF) patients. For prognostic evaluation from different aspects, the utility of combined measurement of the 3 biomarkers in patients with CHF was examined in the present study. Methods and Results Levels of BNP (associated with left ventricular dysfunction, positive if >200 pg/ml), H-FABP (marker of myocardial damage, positive if >4.1 ng/ml), and PTX3 (marker of inflammation, positive if >4.0 ng/ml) were measured in 164 consecutive CHF patients, and patients were prospectively followed with endpoints of cardiac death or rehospitalization. When patients were categorized on the basis of the number of elevated biomarkers, patients with 1, 2, and 3 elevated biomarkers had a 5.4-fold (not significant), 11.2-old (p<0.05), and 34.6-fold increase (p<0.01), respectively, in the risk of adverse cardiac events compared with those without elevated biomarkers. Kaplan-Meier analysis revealed that patients with 3 elevated biomarkers had a significantly higher cardiac event rate than patients with a lower number of elevated biomarkers. Conclusion The combination of these 3 biomarkers could reliably risk-stratify CHF patients for prediction of cardiac events. (Circ J 2008; 72: 1800 - 1805)<br>

収録刊行物

• Circulation Journal

  Circulation Journal 72 (11), 1800-1805, 2008

  一般社団法人 日本循環器学会

キーワード

• Biomarkers
• Chronic heart failure
• Risk stratification

詳細情報

• CRID: 1390001205103188480
• NII論文ID: 110006975572
• NII書誌ID: AA11591968
• DOI: 10.1253/circj.cj-08-0157
• ISSN: 13474820
• ISSN: 13469843
• Web Site: http://www.jstage.jst.go.jp/article/circj/72/11/72_CJ-08-0157/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2009066164
• 本文言語コード: en
• データソース種別:
  • JaLC
  • Crossref
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可